Il percorso di cura dei pazienti con linfoma diffuso a grandi cellule B descritto attraverso i dati amministrativi
This analysis confirms the high rate of rrDlbcl and the high economic impact charged to the SSN to support first the chemo-immunotherapy, then the chronic care and the absence of standardized further lines of therapy for patients with rrDlbcl.
Authors
- Silvia Calabria (ORCID: https://orcid.org/0000-0001-9345-2855)
- Letizia Dondi (ORCID: https://orcid.org/0009-0001-3168-6856)
- Irene Dell’Anno (ORCID: https://orcid.org/0000-0003-0782-8823)
- Leonardo Dondi
- Immacolata Esposito (ORCID: https://orcid.org/0000-0001-7898-6103)
- Alice Addesi
- Carlo Pasquale Piccinni (ORCID: https://orcid.org/0000-0002-8648-8961)
- Giulia Ronconi (ORCID: https://orcid.org/0000-0002-5502-8110)
- Nello Martini
Institutions
- Fondazione Roma (IT)
- Azienda Sanitaria Locale Roma 3 (IT)
Publication Details
- Journal
- Recenti Progressi in Medicina
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1701/4334.43182
- Primary Topic
- Multiple and Secondary Primary Cancers
- Type
- article
- Field-Weighted Citation Impact
- 0.00